Axena Health Gains Additional Funding for its Growth

Axena Health Inc. (Axena Health) has closed an additional $9.4 million in Series A fundraising, with financial support coming from Cross-Border Impact Ventures (CBIV), KOFA Healthcare, Avestria Ventures, and AXA IM Alts through its Global Healthcare Private Equity Strategy. In conjunction with the fundraising round, CBIV Managing Director Donna Parr is joining Axena Health’s Board of Directors.

Proceeds from the fundraising will support Axena Health’s growth. In the United States, the company is focused on the continued commercial launch of its Leva Pelvic Health System, an at-home treatment for urinary incontinence (UI) and chronic fecal incontinence (FI) in women. Outside the Unites States, Axena Health will accelerate its work developing scalable treatments in low- and middle-income countries.

“Over the past year since Axena Health’s founding, we’ve seen remarkable U.S. prescriber adoption and growth in payer coverage, leading to improved patient access. The demand for improved first-line treatment options for urinary incontinence and chronic fecal incontinence is clear and we’re thrilled to partner with CBIV and our existing investors to reach more women across the U.S.,” Axena Health Interium CEO and Chief Financial Officer Jim O’Connor said. “CBIV’s focus on impacting women’s health globally also aligns perfectly with Axena Health’s ongoing work in sub-Saharan Africa to improve access to evidence-based treatments.”

“Pelvic floor disorders are typically progressive conditions and affect women globally,” Parr added. “Too often, women are left with the option of either suffering in silence or pursuing long-term medications or surgical solutions. In our view, neither of those treatments is accessible at scale—particularly not in low resource settings. The Leva Pelvic Health System provides the opportunity to improve access and health outcomes so we couldn’t be more excited to partner on Axena Health’s growth.”

The Leva Pelvic Health System offers a non-invasive, medication-free way for women to train and strengthen their pelvic floor muscles—at home in five minutes a day—to treat UI and FI. Combining a small U.S. Food and Drug Administration-cleared vaginal motion sensor with integrated software, the Leva System offers precise visualization of pelvic movement in real-time, enables progress tracking and allows active physician involvement, all of which support women’s success. Recognizing that level-one evidence shows pelvic floor muscle training is most effective when performed under the supervision of a skilled healthcare provider, the Leva System is available by prescription only, allowing physicians the opportunity to treat UI and chronic FI on a broad scale. The Leva  System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG).

Dr. Zina Affas Besse, Deputy Head of Healthcare Private Equity at AXA IM Alts added, “AXA IM Alts is thrilled to have been Axena Health’s founding investor in 2023. We’re excited to partner with Donna and CBIV as the company works to improve treatment options for more women in the U.S. and globally, in line with our objectives of generating outcomes that benefit people and the planet, while meeting our clients’ financial objectives.”

Axena Health Raises $25 Million in Series A Funding

Axena Health Begins Global Study of Female Incontinence